GlassScriptPhysician profile
David John Bohle
NPI 1710966718
$18,409.53
in general payments reported to CMS, 2019-2025
12 companies · $15.00 in 2025
The $15.00 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2021: $178 · 2022: $307 · 2023: $251 · 2024: $138 · 2025: $15.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,108.26 | 2019-2023 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,927.93 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $4,394.72 | 2019 | |
| Amgen INC. | $255.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $228.51 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $204.03 | 2021-2024 | Xarelto |
| Medtronic, INC. | $156.68 | 2023 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $66.16 | 2019-2024 | Eliquis |
| Abbott Laboratories | $24.25 | 2023 | Amplatzer Talisman |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2019 | |
| Vital Connect, INC | $14.31 | 2024 | Vitalpatch Rtm |
| Medtronic Vascular, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bohle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.